UNSPSC 51202804: Tacrolimus

This classification denotes a mtor inhibitor and immunosuppressant, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier (SRS UNII) WM0HAQ4WNM. European Medicines Agency schedules Tacrolimus in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10797MIG. Tacrolimus generally arises in the molecular formula C44H69NO12.

UNSPSC 51202804 Tacrolimus is a Commodity code that nominally describes a single immunosuppressant pharmaceutical product, yet recent state and local solicitations tagged with this code reveal a much broader procurement landscape spanning emergency medical supplies, naloxone distribution, generic pharmaceuticals, and over-the-counter products. State and local governments are using this code to solicit competitive bids and RFPs for multipurpose medical supply contracts, cooperative purchasing agreements with authorized wholesalers, and direct-to-manufacturer prescription programs that extend well beyond the single-drug scope the code name suggests. The issuing bodies include county health departments, municipal fire and rescue services, state health and human services commissions, and cooperative purchasing alliances representing multiple jurisdictions. Seminole County, Florida; the City of Tampa; the Texas Health and Human Services Commission; and the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) have all posted opportunities under or related to this code in the past six months.

Activity concentrates in Florida and the upper Midwest, with Texas exploring new direct-to-manufacturer models. Representative recent solicitations include Seminole County's IFB for 1,900 units of naloxone and 800 safe drug deactivation systems annually (IFB60459723LAS, due July 26, 2023); the City of Tampa's IFB for 169 line items of medical and first aid supplies for the Tampa Fire Department Rescue Division, valued at $700,000, with a certified Small Local Business Enterprise set-aside and a 5% bid discount (Bid 26P00145, due March 13, 2026); the Texas HHS Commission's RFI on direct-to-manufacturer prescriptions (HHS0017013, response deadline April 3, 2026); and MMCAP's RFP for generic multi-source pharmaceuticals and OTC products to be distributed across participating state and local facilities through authorized wholesalers, with proposals due March 26, 2026 and an effective date of July 1, 2026. These solicitations show demand for both emergency medical response supplies and routine pharmacy benefit procurement through cooperative purchasing vehicles, though the actual scope varies significantly from the code's nominal single-product definition.